{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:15:51Z","timestamp":1781298951353,"version":"3.54.1"},"reference-count":38,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1136\/jnnp-2015-311411","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T01:59:23Z","timestamp":1442282363000},"page":"879-884","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS"],"prefix":"10.1136","volume":"87","author":[{"given":"Mike P","family":"Wattjes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn T","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit I","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlieke","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy D","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M J","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"key":"key-10.1136\/jnnp-2015-311411-1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-pathol-020712-164018","article-title":"Progressive multifocal leukoencephalopathy: why gray and white matter","volume":"8","author":"Gheuens","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"key-10.1136\/jnnp-2015-311411-4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311411-5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-7","unstructured":"Biogen MedInfo. https:\/\/medinfo.biogen.com (March 2015)."},{"key":"key-10.1136\/jnnp-2015-311411-8","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311411-9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00f8rensen","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311411-10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00415-014-7336-5","article-title":"Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?","volume":"261","author":"Wattjes","year":"2014","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","article-title":"MRI pattern in asymptomatic natalizumab-associated PML","volume":"86","author":"Wattjes","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311411-14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","article-title":"MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy","volume":"83","author":"Phan-Ba","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311411-15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00415-012-6759-0","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab","volume":"260","author":"Mc Govern","year":"2013","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-16","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1177\/1352458513510224","article-title":"The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"19","author":"Wattjes","year":"2013","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311411-17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11908-013-0378-5","article-title":"Central nervous system immune reconstitution inflammatory syndrome","volume":"15","author":"Bahr","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"key-10.1136\/jnnp-2015-311411-19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000200","article-title":"Neurological immune reconstitution inflammatory response: riding the tide of immune recovery","volume":"28","author":"Clifford","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab","volume":"71","author":"Kleinschmidt-DeMasters","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy","volume":"123","author":"Metz","year":"2012","journal-title":"Acta Neuropathol"},{"key":"key-10.1136\/jnnp-2015-311411-22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of progressive multifocal leukoencephalopathy associated with natalizumab","volume":"361","author":"Wenning","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311411-23","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Lind\u00e5","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311411-24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311411-25","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"78","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311411-26","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","article-title":"PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids","volume":"72","author":"Tan","year":"2009","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311411-27","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/01.wnl.0000343735.44983.5e","article-title":"Steroids for PML-IRIS: a double-edged sword","volume":"72","author":"Berger","year":"2009","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311411-28","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","article-title":"Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management","volume":"79","author":"Antoniol","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311411-29","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311411-30","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3174\/ajnr.A3183","article-title":"CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome","volume":"34","author":"Post","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"key-10.1136\/jnnp-2015-311411-31","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","article-title":"Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients","volume":"84","author":"Dahlhaus","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311411-32","first-page":"307872","article-title":"PML-IRIS during fingolimod diagnosed after natalizumab discontinuation","volume":"2014","author":"Killestein","year":"2014","journal-title":"Case Rep Neurol Med"},{"key":"key-10.1136\/jnnp-2015-311411-33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00234-003-1115-9","article-title":"Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations","volume":"46","author":"Bergui","year":"2004","journal-title":"Neuroradiology"},{"key":"key-10.1136\/jnnp-2015-311411-34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/13550280600716604","article-title":"Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8+ T cells with JCV-infected glial cells","volume":"12","author":"W\u00fcthrich","year":"2006","journal-title":"J Neurovirol"},{"key":"key-10.1136\/jnnp-2015-311411-35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1212\/WNL.0b013e3181f07362","article-title":"Immune reconstitution inflammatory syndrome after withdrawal of natalizumab","volume":"75","author":"Lenhard","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311411-37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WCO.0000000000000099","article-title":"Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI","volume":"27","author":"Wattjes","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"key-10.1136\/jnnp-2015-311411-38","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp-2013-304986","article-title":"Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?","volume":"84","author":"Wattjes","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2015-311411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:01:03Z","timestamp":1601056863000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2015-311411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,14]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,7,14]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1136\/jnnp-2015-311411"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2015-311411","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,14]]}}}